Cargando…
The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice
Bone marrow-derived mesenchymal stem cells (BMSCs) have recently been introduced to treat cardiovascular diseases, such as myocardial infarction and dilated cardiomyopathy. Nevertheless, there are few researches focused on the application of BMSCs in treating viral myocarditis, not to mention its op...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736900/ https://www.ncbi.nlm.nih.gov/pubmed/29362568 http://dx.doi.org/10.1155/2017/3258035 |
_version_ | 1783287440713187328 |
---|---|
author | Wu, Tingting Xie, Yuan Huang, Jing Li, Ping Wang, Xuliang Yan, Yaoyao Xia, Tianhe Li, Lei Zhu, Feng Li, Hao Wu, Rongzhou |
author_facet | Wu, Tingting Xie, Yuan Huang, Jing Li, Ping Wang, Xuliang Yan, Yaoyao Xia, Tianhe Li, Lei Zhu, Feng Li, Hao Wu, Rongzhou |
author_sort | Wu, Tingting |
collection | PubMed |
description | Bone marrow-derived mesenchymal stem cells (BMSCs) have recently been introduced to treat cardiovascular diseases, such as myocardial infarction and dilated cardiomyopathy. Nevertheless, there are few researches focused on the application of BMSCs in treating viral myocarditis, not to mention its optimal intervention timer potential mechanisms. In our study, we concentrated on finding an optimal time window to perform BMSCs treatment in a murine model of myocarditis induced by coxsackievirus B3 (CVB3). On the 1st day, 3rd day, 7th day, and 14th day after BALB/c mice were infected by CVB3, we intravenously injected equivalent BMSCs into the treatment groups. With a 28-day follow-up after inoculation, we found that the ventricular function was significantly improved in the BMSCs treatment group and cardiac fibrosis markedly ameliorated, especially when BMSCs were injected between 1 and 2 weeks after CVB3 inoculation. Furthermore, we demonstrated that after BMSCs treatment, the expressions of TGF-β, col1α1, and col3α1 were significantly decreased. Therefore, we conclude that BMSCs may have a potential to improve CVB3-induced myocarditis by ameliorating cardiac fibrosis through the inhibition of TGF-β expression. |
format | Online Article Text |
id | pubmed-5736900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-57369002018-01-23 The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice Wu, Tingting Xie, Yuan Huang, Jing Li, Ping Wang, Xuliang Yan, Yaoyao Xia, Tianhe Li, Lei Zhu, Feng Li, Hao Wu, Rongzhou Stem Cells Int Research Article Bone marrow-derived mesenchymal stem cells (BMSCs) have recently been introduced to treat cardiovascular diseases, such as myocardial infarction and dilated cardiomyopathy. Nevertheless, there are few researches focused on the application of BMSCs in treating viral myocarditis, not to mention its optimal intervention timer potential mechanisms. In our study, we concentrated on finding an optimal time window to perform BMSCs treatment in a murine model of myocarditis induced by coxsackievirus B3 (CVB3). On the 1st day, 3rd day, 7th day, and 14th day after BALB/c mice were infected by CVB3, we intravenously injected equivalent BMSCs into the treatment groups. With a 28-day follow-up after inoculation, we found that the ventricular function was significantly improved in the BMSCs treatment group and cardiac fibrosis markedly ameliorated, especially when BMSCs were injected between 1 and 2 weeks after CVB3 inoculation. Furthermore, we demonstrated that after BMSCs treatment, the expressions of TGF-β, col1α1, and col3α1 were significantly decreased. Therefore, we conclude that BMSCs may have a potential to improve CVB3-induced myocarditis by ameliorating cardiac fibrosis through the inhibition of TGF-β expression. Hindawi 2017 2017-12-05 /pmc/articles/PMC5736900/ /pubmed/29362568 http://dx.doi.org/10.1155/2017/3258035 Text en Copyright © 2017 Tingting Wu et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Wu, Tingting Xie, Yuan Huang, Jing Li, Ping Wang, Xuliang Yan, Yaoyao Xia, Tianhe Li, Lei Zhu, Feng Li, Hao Wu, Rongzhou The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice |
title | The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice |
title_full | The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice |
title_fullStr | The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice |
title_full_unstemmed | The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice |
title_short | The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice |
title_sort | optimal intervention time of bone marrow mesenchymal stem cells in ameliorating cardiac fibrosis induced by viral myocarditis: a randomized controlled trial in mice |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736900/ https://www.ncbi.nlm.nih.gov/pubmed/29362568 http://dx.doi.org/10.1155/2017/3258035 |
work_keys_str_mv | AT wutingting theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT xieyuan theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT huangjing theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT liping theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT wangxuliang theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT yanyaoyao theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT xiatianhe theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT lilei theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT zhufeng theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT lihao theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT wurongzhou theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT wutingting optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT xieyuan optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT huangjing optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT liping optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT wangxuliang optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT yanyaoyao optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT xiatianhe optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT lilei optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT zhufeng optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT lihao optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT wurongzhou optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice |